Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results

Compass Therapeutics (NASDAQ:CMPX) issued its quarterly earnings data on Tuesday. The company reported ($0.10) EPS for the quarter, FiscalAI reports.

Compass Therapeutics Trading Down 1.0%

Shares of NASDAQ CMPX opened at $1.94 on Tuesday. The company has a market cap of $349.37 million, a P/E ratio of -4.51 and a beta of 0.79. Compass Therapeutics has a 12-month low of $1.61 and a 12-month high of $6.88. The stock has a fifty day moving average price of $5.18 and a 200 day moving average price of $5.23.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Craig Hallum started coverage on Compass Therapeutics in a research note on Friday, February 13th. They set a “buy” rating and a $15.00 price target on the stock. Guggenheim reaffirmed a “buy” rating and issued a $12.00 target price on shares of Compass Therapeutics in a research report on Tuesday, March 24th. Canaccord Genuity Group cut their price target on shares of Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, April 28th. Raymond James Financial cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 28th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $9.00 target price on shares of Compass Therapeutics in a research note on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $13.60.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its stake in shares of Compass Therapeutics by 3,933.7% in the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after purchasing an additional 7,592 shares during the period. Creative Planning purchased a new stake in Compass Therapeutics during the 2nd quarter worth $30,000. Flagship Harbor Advisors LLC acquired a new position in Compass Therapeutics in the 4th quarter worth $32,000. Strs Ohio acquired a new position in Compass Therapeutics in the 1st quarter worth $34,000. Finally, Apollon Wealth Management LLC purchased a new position in Compass Therapeutics in the 3rd quarter valued at about $35,000. 68.43% of the stock is owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical?stage biotechnology company dedicated to the discovery and development of novel immuno?oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti?tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47?SIRP? pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.